Somatostatin analogues in treatment-refractory meningioma: a systematic review with meta-analysis of individual patient data

Somatostatin analogues in treatment-refractory meningioma: a systematic review with meta-analysis of individual patient data

Treatment-refractory meningiomas have a dismal prognosis and limited treatment options. Meningiomas express high-densities of somatostatin receptors (SSTR), thus potentially susceptible to antitumorigenic effects of somatostatin analogues (SSA). Evidence for SSA in meningiomas is scarce, and it is u...

Full description

Saved in:
Bibliographic Details
Published in:Neurosurgical review Vol. 45; no. 5; pp. 3067 - 3081
Main Authors: Jensen, Lasse Rehné, Maier, Andrea Daniela, Lomstein, Atle, Graillon, Thomas, Hrachova, Maya, Bota, Daniela, Ruiz-Patiño, Alejandro, Arrieta, Oscar, Cardona, Andrés Felipe, Rudà, Roberta, Furtner, Julia, Roeckle, Ulrich, Clement, Paul, Preusser, Matthias, Scheie, David, Broholm, Helle, Kristensen, Bjarne Winther, Skjøth-Rasmussen, Jane, Ziebell, Morten, Munch, Tina Nørgaard, Fugleholm, Kåre, Walter, Martin A., Mathiesen, Tiit, Mirian, Christian
Format: Journal Article
Language:English
Published: Berlin/Heidelberg Springer Berlin Heidelberg 01-10-2022
Subjects:
Medicin och hälsovetenskap
Medicine
Medicine & Public Health
Neurosurgery
Review
Progressive
Neuro-oncology
Treatment-refractory
Meningioma
Meta-analysis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treatment-refractory meningiomas have a dismal prognosis and limited treatment options. Meningiomas express high-densities of somatostatin receptors (SSTR), thus potentially susceptible to antitumorigenic effects of somatostatin analogues (SSA). Evidence for SSA in meningiomas is scarce, and it is unclear if published literature would either (1) support wider use of SSA, if (2) more evidence is desirable, or if (3) available evidence is sufficient to discard SSA. We addressed the need for more evidence with a systematic review and meta-analysis. We performed an individual patient data (IPD) meta-analysis. Main outcomes were toxicity, best radiological response, progression-free survival, and overall survival. We applied multivariable logistic regression models to estimate the effect of SSA on the probability of obtaining radiological disease control. The predictive performance was evaluated using area under the curve and Brier scores. We included 16 studies and compiled IPD from 8/9 of all previous cohorts. Quality of evidence was overall ranked “very low.” Stable disease was reported in 58% of patients as best radiological response. Per 100 mg increase in total SSA dosage, the odds ratios for obtaining radiological disease control was 1.42 (1.11 to 1.81, P  = 0.005) and 1.44 (1.00 to 2.08, P  = 0.05) for patients treated with SSA as monodrug therapy vs SSA in combination with everolimus, respectively. Low quality of evidence impeded exact quantification of treatment efficacy, and the association between response and treatment may represent reverse causality. Yet, the SSA treatment was well tolerated, and beneficial effect cannot be disqualified. A prospective trial without bias from inconsistent study designs is warranted to assess SSA therapy for well-defined meningioma subgroups.
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Review-1
ObjectType-Article-3
ObjectType-Undefined-4
ISSN:1437-2320
0344-5607
1437-2320
DOI:10.1007/s10143-022-01849-6